Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung × Tyrosine Kinase Inhibitors × Clear all

NCT04777994 2026-06-04

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

Phase 1 Recruiting

GenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasms, Recurrence

NCT03958565 2026-06-03

Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.

Carcinoma, Non-Small-Cell Lung

NCT03611738 2026-05-15

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02949843 2024-06-28

Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations

Phase 2 Terminated

19 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT01859026 2023-01-19

A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01999985 2020-11-27

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Phase 1 Completed

25 enrolled 10 charts

Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Pleural Diseases, Pleural Effusion, Pleural Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Pleural Effusion, Malignant

NCT03799094 2019-01-10

Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations

Phase 1/2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03424980 2018-02-08

A Study to Evaluate Effectiveness and Safety of Tyrosine Kinase Inhibitors

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT02906163 2016-09-19

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

Phase 1/2 Unknown

Carcinoma, Non-Small-Cell Lung